Search

Your search keyword '"Pirttilä, Tuula"' showing total 324 results
Start Over Author "Pirttilä, Tuula"
324 results on '"Pirttilä, Tuula"'

51. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.

Author

Leinonen, Ville, Alafuzoff, Irina, Aalto, Sargo, Suotunen, Timo, Savolainen, Sakari, Någren, Kjell, Tapiola, Tero, Pirttilä, Tuula, Rinne, Jaakko, Jääskeläinen, Juha E, Soininen, Hilkka, Rinne, Juha O, Leinonen, Ville, Alafuzoff, Irina, Aalto, Sargo, Suotunen, Timo, Savolainen, Sakari, Någren, Kjell, Tapiola, Tero, Pirttilä, Tuula, Rinne, Jaakko, Jääskeläinen, Juha E, Soininen, Hilkka, and Rinne, Juha O

Abstract

OBJECTIVE: To compare carbon 11-labeled Pittsburgh Compound B ([11C]PiB) positron emission tomography (PET) findings in patients with and without Alzheimer disease lesions in frontal cortical biopsy specimens. DESIGN: Cross-sectional study of [11C]PiB PET findings in patients with or without beta-amyloid (Abeta) aggregates in frontal cortical biopsy specimens. SETTING: Two university hospitals in Finland. Patients Ten patients who had undergone intraventricular pressure monitoring with a frontal cortical biopsy (evaluated for Abeta aggregates and hyperphosphorylated tau) for suspected normal-pressure hydrocephalus. INTERVENTIONS: [11C]PiB PET and evaluation for cognitive impairment using a battery of neuropsychological tests. MAIN OUTCOME MEASURES: Immunohistochemical evaluation for Abeta aggregates and hyperphosphorylated tau in the frontal cortical biopsy specimen and [11C]PiB PET. RESULTS: In patients with Abeta aggregates in the frontal cortical biopsy specimen, PET imaging revealed higher [11C]PiB uptake (P < .05) in the frontal, parietal, and lateral temporal cortices and in the striatum as compared with the patients without frontal Abeta deposits. CONCLUSIONS: Our study supports the use of noninvasive [11C]PiB PET in the assessment of Abeta deposition in the brain. Large prospective studies are required to verify whether [11C]PiB PET will be a diagnostic aid, particularly in early Alzheimer disease.

Published
2008
Full Text
View/download PDF

53. Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease

Author

Leinonen, Ville, primary, Koivisto, Anne M., additional, Savolainen, Sakari, additional, Rummukainen, Jaana, additional, Tamminen, Juuso N., additional, Tillgren, Tomi, additional, Vainikka, Sannakaisa, additional, Pyykkö, Okko T., additional, Mölsä, Juhani, additional, Fraunberg, Mikael, additional, Pirttilä, Tuula, additional, Jääskeläinen, Juha E., additional, Soininen, Hilkka, additional, Rinne, Jaakko, additional, and Alafuzoff, Irina, additional

Published
2010
Full Text
View/download PDF

54. O2-02-01: Prediction of Alzheimer's disease by beta-amyloid plaques and tau protein in frontal cortical biopsy

Author

Leinonen, Ville, primary, Koivisto, Anne M., additional, Rummukainen, Jaana, additional, Tamminen, Juuso, additional, Tillgren, Tomi, additional, Vainikka, Sannakaisa, additional, Savolainen, Sakari, additional, Pyykkö, Okko, additional, Fraunberg, Mikael, additional, Pirttilä, Tuula, additional, Jääskeläinen, Juha E., additional, Soininen, Hilkka, additional, Rinne, Jaakko, additional, and Alafuzoff, Irina, additional

Published
2010
Full Text
View/download PDF

57. MYO9B polymorphisms in multiple sclerosis

Author

Kemppinen, Anu, primary, Suvela, Minna, additional, Tienari, Pentti J, additional, Elovaara, Irina, additional, Koivisto, Keijo, additional, Pirttilä, Tuula, additional, Reunanen, Mauri, additional, Rautakorpi, Ilkka, additional, Hillert, Jan, additional, Lundmark, Frida, additional, Oturai, Annette, additional, Ryder, Lars, additional, Harbo, Hanne F, additional, Celius, Elisabeth G, additional, Palotie, Aarno, additional, Daly, Mark, additional, Peltonen, Leena, additional, and Saarela, Janna, additional

Published
2009
Full Text
View/download PDF

59. P3-450: ALSOVA: A prospective intervention follow-up study on recently diagnosed patients with mild Alzheimer's disease and their caregivers-the study population at the baseline

Author

Herukka, Sanna-Kaisa, primary, Välimäki, Tarja, additional, Pietilä, Anna-Maija, additional, Vehviläinen-Julkunen, Katri, additional, Martikainen, Janne, additional, Valtonen, Hannu, additional, Sivenius, Juhani, additional, Soininen, Hilkka, additional, Karppi, Pertti, additional, Hiltunen, Asta, additional, and Pirttilä, Tuula, additional

Published
2008
Full Text
View/download PDF

60. P3-073: CSF Aβ42, Tau and phosphorylated Tau are biomarkers for Alzheimer's disease neuropathology and predict development of Alzheimer's disease in patients with mild cognitive impairment

Author

Herukka, Sanna-Kaisa, primary, Tapiola, Tero, additional, Hallikainen, Merja, additional, Tervo, Susanna, additional, Helisalmi, Seppo, additional, Pennanen, Corina, additional, Alafuzoff, Irina, additional, Soininen, Hilkka, additional, and Pirttilä, Tuula, additional

Published
2008
Full Text
View/download PDF

63. Synergistic effect of apolipoprotein E ε4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease

Author

Lane, Roger, primary, Feldman, Howard H., additional, Meyer, Joanne, additional, He, Yunsheng, additional, Ferris, Steven H., additional, Nordberg, Agneta, additional, Darreh-Shori, Taher, additional, Soininen, Hilkka, additional, Pirttilä, Tuula, additional, Farlow, Martin R., additional, Sfikas, Nikolaos, additional, Ballard, Clive, additional, and Greig, Nigel H., additional

Published
2008
Full Text
View/download PDF

69. S4-01-02

Author

Buerger, Katharina, primary, Teipel, Stefan J., additional, Zinkowski, Ray, additional, Pirttilä, Tuula, additional, Alafuzoff, Irina, additional, Blennow, Kaj, additional, and Hampel, Harald, additional

Published
2006
Full Text
View/download PDF

73. Reply

Author

Parkkinen, Laura, primary, Kauppinen, Tarja, additional, Pirttilä, Tuula, additional, Autere, Jaana M., additional, and Alafuzoff, Irina, additional

Published
2005
Full Text
View/download PDF

81. Interleukin-18 alters protein expressions of neurodegenerative diseases-linked proteins in human SH-SY5Y neuron-like cells.

Author

Sutinen, Elina M., Korolainen, Minna A., Häyrinen, Jukka, Alafuzoff, Irina, Petratos, Steven, Salminen, Antero, Soininen, Hilkka, Pirttilä, Tuula, and Ojala, Johanna O.

Subjects
INTERLEUKIN-18, PROTEIN expression, NEURODEGENERATION, ALZHEIMER'S disease, AMYLOID plaque, NEUROFIBRILLARY tangles, GEL electrophoresis, WESTERN immunoblotting
Abstract

Chronic inflammation and oxidative stress (OS) are present in Alzheimer's disease (AD) brains in addition to neuronal loss, Amyloid-β(Aβ) plaques and hyperphosphorylated tau-protein neurofibrillary tangles (NFTs). Previously we showed that levels of the pro-inflammatory cytokine, interleukin-18 (IL-18), are elevated in post-mortem AD brains. IL-18 can modulate the tau kinases, Cdk5 and GSK3β, as well as Aβ-production. IL-18 levels are also increased in AD risk diseases, including type-2 diabetes and obesity. Here, we explored other IL-18 regulated proteins in neuron-like SH-SY5Y cells. Differentiated SH-SY5Y cells, incubated with IL-18 for 24, 48, or 72 h, were analyzed by two-dimensional gel electrophoresis (2D-DIGE). Specific altered protein spots were chosen and identified with mass spectrometry (MS) and verified by western immunoblotting (WIB). IL-18 had time-dependent effects on the SH-SY5Y proteome, modulating numerous protein levels/modifications. We concentrated on those related to OS (DDAH2, peroxiredoxins 2, 3, and 6, DJ-1, BLVRA), Aβ-degradation (MMP14, TIMP2), Aβ-aggregation (Septin-2), and modifications of axon growth and guidance associated, collapsin response mediator protein 2 (CRMP2). IL-18 significantly increased antioxidative enzymes, indicative of OS, and altered levels of glycolytic α- and γ-enolase and multifunctional 14-3-3γ and -ε, commonly affected in neurodegenerative diseases. MMP14, TIMP2, α-enolase and 14-3-3ε, indirectly involved in Aβmetabolism, as well as Septin-2 showed changes that increase Aβlevels. Increased 14-3-3γ may contribute to GSK3βdriven tau hyperphosphorylation and CRMP2 Thr514 and Ser522 phosphorylation with the Thr555-site, a target for Rho kinase, showing time-dependent changes. IL-18 also increased caspase-1 levels and vacuolization of the cells. Although our SH-SY5Y cells were not aged, as neurons in AD, our work suggests that heightened or prolonged IL-18 levels can drive protein changes of known relevance to AD pathogenesis. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

90. Neuropsychiatric symptoms and Quality of Life in patients with very mild and mild Alzheimer's disease.

Author

Karttunen, Kristiina, Karppi, Pertti, Hiltunen, Asta, Vanhanen, Matti, Välimäki, Tarja, Martikainen, Janne, Valtonen, Hannu, Sivenius, Juhani, Soininen, Hilkka, Hartikainen, Sirpa, Suhonen, Jaana, and Pirttilä, Tuula

Subjects
ALZHEIMER'S disease, CHI-squared test, COMPUTER software, STATISTICAL correlation, FACTOR analysis, INTERVIEWING, QUALITY of life, REGRESSION analysis, RESEARCH funding, STATISTICS, T-test (Statistics), DATA analysis, VISUAL analog scale, SYMPTOMS, PSYCHOLOGY
Abstract

Background: Neuropsychiatric symptoms (NPS) are common manifestations of Alzheimer’ s disease (AD). Objective: To examine the prevalence and significance of NPS in very mild and mild AD patients with emphasis on their influence on the well-being of the patients and their caregivers. Methods: The participants were 240 patient-caregiver dyads who participated in a prospective, controlled rehabilitation study (ALSOVA). Three Quality of Life (QoL) instruments were used; generic 15D, disease-specific QoL-AD and Visual Analog Scale (VAS). The disease-specific QoL-AD was both selfrated and caregiver rated. Other scales used were Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), ADCS-ADL, Neuropsychiatric Inventory (NPI) and Beck Depression Inventory (BDI). Results: NPS were present in 76.5% of patients with very mild AD (CDR 0.5) and in 84.9% of patients with mild to moderate AD (CDR 1). The most frequent symptoms were apathy, depression, irritability, and agitation. The strongest predictor of self-reported QoL-AD scores was depressive symptoms whereas functional decline and presence of NPS predicted poor caregiver ratings of patients’ QoL. However, caregiver depression also influenced significantly their ratings. Conclusion: NPS are common even in the early stages of AD. NPS were significantly associated with caregiver assessment of the patient’s QoL but not with patients’ self-assessed QoL. Depression decreases QoL, but may remain unrecognized in AD patients, emphasizing the need for careful and structured assessment of NPS before deciding on the appropriate treatment. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

91. Quantification of 1H NMR spectra of human cerebrospinal fluid: a protocol based on constrained total-line-shape analysis.

Author

Jukarainen, Niko, Korhonen, Samuli-Petrus, Laakso, Mikko, Korolainen, Minna, Niemitz, Matthias, Soininen, Pasi, Tuppurainen, Kari, Vepsäläinen, Jouko, Pirttilä, Tuula, and Laatikainen, Reino

Abstract

A protocol for quantitative 1H NMR analysis of human cerebrospinal fluid (hCSF) was built up and assessed as based on Constrained Total-Line-Shape (CTLS) fitting. In this method, linear constraints were applied to spectral structures. The 1H NMR spectra of 45 human CSF samples were measured and quantified using the CTLS method. The quantification strategies based on total-line-shape fitting are discussed. The metabolic model for CTLS includes 31 metabolites covering 85% of the total spectral intensity, excluding the protein contribution. Prior to data analysis, the data was divided into patients with no Alzheimer’s disease (AD), but with a normal AD marker profile (the peptide β-amyloid42 and tau protein) present in CSF, and into controls that do not have an AD marker profile in CSF. Unexpectedly large variations in metabolite concentrations within the two patient groups were detected, but an analysis of variance revealed a significant ( P = 0.027) difference only in the concentration of creatinine which was higher in patients that had a normal AD marker profile. Multivariate classification tools such as self-organizing maps (SOM) failed in separation of the two classes. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

97. Synergistic effect of apolipoprotein E 4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease

Author

Lane, Roger, Feldman, Howard H., Meyer, Joanne, He, Yunsheng, Ferris, Steven H., Nordberg, Agneta, Darreh-Shori, Taher, Soininen, Hilkka, Pirttilä, Tuula, Farlow, Martin R., Sfikas, Nikolaos, Ballard, Clive, and Greig, Nigel H.

Abstract

To evaluate the synergistic effects of the apolipoprotein E (APOE) 4 and butyrylcholinesterase K-variant (BCHE-K) alleles on progression to Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI).

Published
2008
Full Text
View/download PDF

98. Blood Pressure and Survival in the Very Old.

Author

Juva, Kati, Rastas, Sari, and Pirttilä, Tuula

Abstract

The article examines the association between blood pressure (BP) and survival in older adults. It notes the negative impacts of high PB on cardiovascular mortality and morbidity. It discusses several studies that reveal the importance of high BP for the survival in the very old and the negative effects of lowering high BP, including the Helsinki Aging Study, the Vantaa 85+Study and the Kungsholmen Study. It also explores the complexity of hypertension in older adults.

Published
2007

99. CSF A42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment

Author

Herukka, Sanna-Kaisa, Hallikainen, Merja, Soininen, Hilkka, and Pirttilä, Tuula

Abstract

Baseline CSF amyloid -peptide-42 (A42), tau, and phosphorylated tau (P-tau) levels from 46 control subjects and 78 patients with mild cognitive impairment (MCI) were measured. Twenty-three patients with MCI developed dementia during the study. Abnormal biomarkers were found early in the course of Alzheimer disease (AD). The most predictive assay for AD among the patients with MCI was the combination of A42 and P-tau.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results